Horton et pseudo-polyarthrite rhizomélique
Veille bibliographique : Horton et PPR
Les articles sont classés du plus ancien au plus récent, n’hésitez pas à utiliser la barre de recherche pour filtrer les résultats par date par exemple.
| Singh AG et al. Visual Manifestations in Giant Cell Arteritis: Trend over 5 Decades in a Population-based Cohort. J Rheumatol. 2015 Feb;42(2):309-15. doi: 10.3899/jrheum.140188. Epub 2014 Dec 15 | Lire le résumé |
| Villiger PM et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Lond Engl. 4 mars 2016 | Lire le résumé |
| Alsolaimani RS et al. Severe Intracranial Involvement in Giant Cell Arteritis: 5 Cases and Literature Review. J Rheumatol. mars 2016;43(3):648‑56 | Lire le résumé |
| Stone JH et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017 27;377(4):317–28. | Lire le résumé |
| Devauchelle-Pensec V et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis. août 2016;75(8):1506‑10. | Lire le résumé |
| Belkhir R et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017 Jun 9 | Lire le résumé |
| Conway R, Smyth AE, Kavanagh RG, O’Donohoe RL, Purcell Y, Heffernan EJ, et al. Diagnostic Utility of Computed Tomographic Angiography in Giant-Cell Arteritis. Stroke. 2018 Sep;49(9):2233–6. | Lire le résumé |
| Inciarte-Mundo J, Ramirez J, Hernández MV, Ruiz-Esquide V, Cuervo A, Cabrera-Villalba SR, et al. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study. Arthritis Research & Therapy [Internet]. 2018 Dec [cited 2018 Dec 19];20(1) | Lire le résumé |
| Nielsen BD, Gormsen LC, Hansen IT, Keller KK, Therkildsen P, Hauge E-M. Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy. European Journal of Nuclear Medicine and Molecular Imaging. 2018 Jul;45(7):1119–28 | Lire le résumé |
| Writing group, , Reviewer group, Members of EANM Cardiovascular, Members of EANM Infection & Inflammation, Members of Committees, SNMMI Cardiovascular, Members of Council, PET Interest Group, et al. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. European Journal of Nuclear Medicine and Molecular Imaging. 2018 Jul;45(7):1250–69 | Lire le résumé |
| Stones JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Glucocorticoid Doses and Acute-Phase Reactants at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. Arthritis Rheumatol [Internet]. 5 mars 2019 [cité 26 mars 2019]; Disponible sur: http://doi.wiley.com/10.1002/art.40876 | Lire le résumé |
| Calderón-Goercke M, Loricera J, Aldasoro V, Castañeda S, Villa I, Humbría A, et al. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. Semin Arthritis Rheum [Internet]. janv 2019 [cité 26 mars 2019]; Disponible sur: https://linkinghub.elsevier.com/retrieve/pii/S0049017218305717 | Lire le résumé |
| Nannini C, Niccoli L, Sestini S, Laghai I, Coppola A, Cantini F. Remission maintenance after tocilizumab dose-tapering and interruption in patients with giant cell arteritis: an open-label, 18-month, prospective, pilot study. Ann Rheum Dis. oct 2019;78(10):1444 6 | Lire le résumé |
| Adler S, Reichenbach S, Gloor A, Yerly D, Cullmann JL, Villiger PM. Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. Rheumatology. 1 sept 2019;58(9):1639 43 | Lire le résumé |
| Gribbons KB, Ponte C, Carette S, Craven A, Cuthbertson D, Hoffman GS, et al. Patterns of Arterial Disease in Takayasu’s Arteritis and Giant Cell Arteritis. Arthritis Care Res [Internet]. 23 août 2019 [cité 15 oct 2019]; | Lire le résumé |
| Rubenstein E, Maldini C, Gonzalez-Chiappe S, Chevret S, Mahr A. Sensitivity of temporal artery biopsy in the diagnosis of giant cell arteritis: a systematic literature review and meta-analysis. Rheumatology [Internet]. 14 sept 2019 [cité 29 oct 2019]; | Lire le résumé |
| Michailidou D, Rosenblum JS, Rimland CA, Marko J, Ahlman MA, Grayson PC. Clinical symptoms and associated vascular imaging findings in Takayasu’s arteritis compared to giant cell arteritis. Ann Rheum Dis. 24 oct 2019;annrheumdis-2019-216145 | Lire le résumé |
| Sammel AM, Smith S, Nguyen K, Laurent R, Brewer J, Hall N, et al. Assessment for varicella zoster virus in patients newly suspected of having giant cell arteritis. Rheumatology [Internet]. 27 nov 2019 [cité 10 déc 2019] | Lire le résumé |
| van der Geest KSM, Borg F, Kayani A, Paap D, Gondo P, Schmidt W, et al. Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia. Ann Rheum Dis. 3 janv 2020;annrheumdis-2019-216343. | Lire le résumé |
| Koster MJ, Yeruva K, Crowson CS, Muratore F, Labarca C, Warrington KJ. Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study. J Rheumatol. mai 2019;46(5):501 8. | Lire le résumé |
| Fernández-Fernández E, Monjo-Henry I, Bonilla G, Plasencia C, Miranda-Carús M-E, Balsa A, et al. False positives in the ultrasound diagnosis of giant cell arteritis: some diseases can also show the halo sign. Rheumatology [Internet]. 18 janv 2020 [cité 20 févr 2020] | Lire le résumé |
| Borresen SW, Thorgrimsen TB, Jensen B, Hilsted L, Bartels EM, Feldt-Rasmussen U, et al. Adrenal insufficiency in prednisolone-treated patients with polymyalgia rheumatica or giant cell arteritis—prevalence and clinical approach. Rheumatology [Internet]. 7 févr 2020 [cité 20 févr 2020]; | Lire le résumé |
| Matza MA, Fernandes AD, Stone JH, Unizony SH. Ustekinumab for the Treatment of Giant Cell Arteritis. Arthritis Care Res [Internet]. 5 avr 2020 [cité 17 avr 2020] | Lire le résumé |
| Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol. août 2021;73(8):1349‑65. | Lire le résumé |
| Venhoff N, Schmidt WA, Bergner R, Rech J, Unger L, Tony HP, et al. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Rheumatol. juin 2023;5(6):e341‑50. | Lire le résumé |
| Spiera RF, Unizony S, Warrington KJ, Sloane J, Giannelou A, Nivens MC, et al. Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper. N Engl J Med. 5 oct 2023;389(14):1263‑72 | Lire le résumé |
| Billet AC, Thibault T, Liozon É, De Boysson H, Perard L, Espitia O, et al. Prognostic value of 18 FDG-PET at diagnosis and follow-up in giant cell arteritis: An observational restrospective study. Eur J Intern Med. avr 2024;S0953620524001456 | Lire le résumé |